Glenmark Pharma.
Ticker > Company >

Glenmark Pharma. share price

Glenmark Pharmaceuticals Ltd.

  3.19 L   1.39 K   227 NSE: GLENMARK BSE: 532296 SECTOR: Pharmaceuticals & Drugs

2246.50
-58.50 (-2.54%)
NSE: 19 Aug 4:00 PM

Buy on Angel One

Price Summary

Today's High

₹ 2313.9

Today's Low

₹ 2222.5

52 Week High

₹ 2474

52 Week Low

₹ 1792.6

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 63401.77 Cr.

Enterprise Value

₹ 63108.58 Cr.

No. of Shares

28.22 Cr.

P/E

309.86

P/B

2.55

Face Value

₹ 1

Div. Yield

0.11 %

Book Value (TTM)

₹  881.65

CASH

₹ 293.19 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

46.65 %

EPS (TTM)

₹  7.25

Sales Growth

-8.52%

ROE

-0.83 %

ROCE

-0.76%

Profit Growth

-112.47 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Glenmark Pharmaceuticals Ltd.

CANDID ALEX-P SYRUP SIBUTRIM GLINATE LEREZ VORTH-XT STRONAT ERDOZET DYCERIN FINTOP SIBET NITAZET-O ONABET ESOZ - D COLY-MONAS PALNOX AIRTEC-FB BORTRAC GEFTIB TAZRET EVERMIL GLUCAR ZINOX TACROZ FORTE FLEXILOR MIGNAR ASCORIL PLUS TACROZ

Index Presence

The company is present in 39Indices.

NFT150MOM50

Nifty Midcap150 Momentum 50
63655.7
  -481.400000000001 (-0.750579617725156%)

NIFTYMIDCAP

NIFTY Midcap 100
63408.75
  -130.650000000001 (-0.205620449673749%)

NIFTYALPHA

Nifty Alpha 50
55776.95
  -677.400000000001 (-1.19990753591176%)

NFT500MOM50

Nifty500 Momentum 50
54442.1
  -649.400000000001 (-1.17876623435558%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
51772.7
  -459.75 (-0.880199952328486%)

NYMIDSML400MQ100

Nifty MidSmallcap400 Momentum Quality 100 Index
51719.05
  -312.699999999997 (-0.600979209809394%)

NFTY200MOM30

Nifty200 Momentum 30
30781.15
  -338.099999999999 (-1.08646577279337%)

NT200ALP30

NIFTY200 Alpha 30
26478.45
  -281.799999999999 (-1.05305443708485%)

NIFTYPHARMA

Nifty Pharma
26313.8
  -48.1000000000022 (-0.182460293074482%)

NIFTY500

Nifty 500
23386.2
  -86.2000000000007 (-0.367239822088927%)

NIFTYMIDCAP150

Nifty Midcap 150
23305.6
  -59.3000000000029 (-0.253799502672825%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
21461.25
  -82.1500000000015 (-0.381323282304569%)

NFT500HEALTH

Nifty500 Healthcare Index
21437.55
  -110.5 (-0.512807423409545%)

NFTMIDSML40050:50

Nifty MidSmallcap400 50:50
20915.55
  -92.4000000000015 (-0.439833491606756%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
18588.4
  -77.3499999999985 (-0.414395349771635%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
16943.9
  -79.5999999999985 (-0.46758892119716%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
16777
  -51.6500000000015 (-0.306917072967838%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
16600.5
  -66.7999999999993 (-0.40078477017873%)

NIFTYHEALTH

Nifty Healthcare Index
16412.8
  -50.9000000000015 (-0.309165011510182%)

NFT500EQUAL

Nifty 500 Equal Weight
15031.8
  -73.1500000000015 (-0.484278332599586%)

NIFTY200

Nifty 200
14020.3
  -46.3500000000004 (-0.329502760074363%)

NIFTYTOTALMCAP

NIFTY Total Market
13211.75
  -50 (-0.37702414839671%)

SHARIAH500

Nifty500 Shariah
7012.3
  -22.6499999999996 (-0.321963908769785%)

NIFTYFPI150

Nifty India FPI 150
1567.05
  -4.90000000000009 (-0.311714749196867%)

BSEMID150MOM30

BSE Midcap 150 Momentum 30 Index
129467.89
  -1333.55 (-1.01952241504375%)

BSE HC

Bse Healthcare
50591.48
  -222.349999999999 (-0.437577722442883%)

BSE500MOM50

BSE 500 Momentum 50
46080.01
  -593.220000000001 (-1.27100695623594%)

MIDCAP

Bse MidCap
44246.27
  -699.210000000006 (-1.55568479856041%)

BSE500

Bse 500
36577.15
  -172.080000000002 (-0.46825470901023%)

MID150

Bse 150 MidCap Index
17170.36
  -76.2099999999991 (-0.441884966112094%)

MSL400

Bse 400 MidSmallCap Index
12821.04
  -66.9899999999998 (-0.519784637372811%)

S&P MIDSMLCAP

Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

BSE1000

Bse 1000
10964.25
  -51.9799999999996 (-0.471849262406465%)

LMI250

Bse 250 LargeMidCap Index
10812.58
  -48.2100000000009 (-0.443890361566712%)

S&P LARGEMIDCAP

Bse LargeMidCap
10319.66
  72.75 (0.709970127579918%)

ALLCAP

Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

LARGEMID(60:40)

BSE LargeMid (60:40) Stable Dividend 50 Index
3654.43
  -18.0800000000004 (-0.492306351786664%)

SPBSMOIP

BSE Momentum Index
2230.87
  -10.9700000000003 (-0.489330193055715%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-8.52%
3 Year0.88%
5 Year2.21%

Profit Growth

1 Year-112.47%
3 Year-154.97%
5 Year-165.63%

ROE%

1 Year-0.83%
3 Year10.42%
5 Year10.18%

ROCE %

1 Year-0.76%
3 Year13.62%
5 Year12.54%

Debt/Equity

0

Price to Cash Flow

116.7

Interest Cover Ratio

-2.3789

CFO/PAT (5 Yr. Avg.)

0.340043440930556

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 46.65 0.00
Mar 2026 46.65 0.00
Dec 2025 46.65 0.00
Sep 2025 46.65 0.00
Jun 2025 46.65 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 698.82 Cr.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of -131.3239 days.

 Limitations

  • The company has shown a poor profit growth of -154.97173075239% for the Past 3 years.
  • The company has shown a poor revenue growth of 0.881967745904499% for the Past 3 years.
  • The company is trading at a high EV/EBITDA of 35.5772.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 2394.93 1538.66 2359.94 2146.58 2434.99
Total Expenditure 1666.77 1716.66 1864.23 2115.05 1821.74
Operating Profit 728.16 -178 495.71 31.53 613.25
Other Income 69.34 285.76 109.06 307.88 115.41
Interest 15.46 23.4 21.98 17.91 23.25
Depreciation 57.64 58.93 59.18 60.13 62.32
Exceptional Items -323.23 -931.79 -177.07 -368.76 223
Profit Before Tax 401.17 -906.37 346.53 -107.4 866.1
Tax 70.94 -167.18 64.46 -33.5 130.47
Profit After Tax 330.23 -739.19 282.07 -73.9 735.64
Adjusted EPS (Rs) 11.7 -26.19 10 -2.62 26.07

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 8141.58 8220.66 7891.12 9226.41 8440.1
Total Expenditure 6453.36 6747.9 6649.46 6982.23 7362.7
Operating Profit 1688.22 1472.77 1241.66 2244.18 1077.4
Other Income 614.63 985.94 1168.02 356.37 772.02
Interest 236.04 206.82 277.11 48.73 78.75
Depreciation 159.7 184.15 202.16 218.63 235.89
Exceptional Items 430.33 -495.87 5070.33 -179.17 -1800.86
Profit Before Tax 2337.45 1571.87 7000.75 2154.02 -266.07
Tax 339.66 363.11 1833.46 543.67 -65.27
Net Profit 1997.79 1208.77 5167.29 1610.35 -200.8
Adjusted EPS (Rs.) 70.8 42.84 183.11 57.07 -7.12

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 28.22 28.22 28.22 28.22 28.22
Total Reserves 16710.37 17849.25 22942.4 24475.74 24122.1
Borrowings 2571.74 2660.82 0 0 0
Other N/C liabilities 1412.85 2394.32 3286.93 5020.36 6396.73
Current liabilities 4896.21 3991.95 5152.18 3245.91 3669.03
Total Liabilities 25619.39 26924.55 31409.72 32770.22 34216.08
Assets
Net Block 1752.33 1745.94 1756.25 1979.18 2027.9
Capital WIP 101.17 159.07 175.5 121.34 67.36
Intangible WIP 7.87 13.27 22.17 33.22 91.96
Investments 8559.39 10332.71 12964.79 15194.91 15202.21
Loans & Advances 9335.01 9934.57 10940.59 10659.14 10729.4
Other N/C Assets 5.55 3.63 6.18 4.77 2.16
Current Assets 5858.08 4735.35 5544.26 4777.67 6095.1
Total Assets 25619.39 26924.55 31409.72 32770.22 34216.08
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 2337.45 1571.87 7000.75 2154.02 -266.07
Adjustment -617.5 122.48 -5884.79 123.92 1546.57
Changes in Assets & Liabilities -113.17 196.13 -740.31 -1106.26 -656.2
Tax Paid -390.72 -416.42 -871.1 -582.88 -81
Operating Cash Flow 1216.07 1474.06 -495.45 588.8 543.3
Investing Cash Flow -897.02 -431.52 3197.17 -489.9 569.21
Financing Cash Flow -305.12 -978.5 -2666.45 -95.41 -952.13
Net Cash Flow 13.93 64.05 35.27 3.49 160.38

Corporate Actions

Investors Details

PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
promoters 46.65 46.65 46.65 46.65 46.65
blanche elizabeth saldanh... 0.39 0.39 0.39 0.39 0.39
cherylann maria pinto 0.27 0.27 0.27 0.27 0.27
glenn mario saldanha 0.35 0.35 0.36 0.36 0.36
neha saldanha 0.01 0.01 0.01 0.01 0.01
robin joseph pinto 0.18 0.18 0.18 0.18 0.18
saldanha family trust 45.44 45.44 45.44 45.44 45.44
PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
investors 53.35 53.35 53.35 53.35 53.35
amansa holdings private l... 1.44 2.07 2.22 2.22 2.22
bandhan nifty 200 momentu... - - - - 1.28
government pension fund g... 3.21 3.52 3.49 3.78 3.89
hdfc mutual fund - hdfc m... - 6.20 - - 6.22
invesco india contra fund... - - - - 2.20
investor education and pr... - - 0.10 - 0.09
uti multi cap fund - - - - 1.15
investor education and p... - - - 0.10 -
bandhan balanced advantag... - - - 1.17 -
hdfc mutual fund - hdfc n... - - - 6.11 -
invesco india large & mid... - - 2.38 1.88 -
uti-healthcare fund - - - 1.27 -
bandhan multi-factor fund... - - 1.23 - -
hdfc mutual fund-hdfc arb... - - 6.15 - -
uti aggressive hybrid fun... - - 1.30 - -
invesco india flexi cap f... - 2.04 - - -
investor education and pr... 0.09 0.09 - - -
mirae asset nifty midcap ... - 1.33 - - -
smallcap world fund, inc 2.11 2.01 - - -
3p india equity fund 1 1.02 - - - -
ashish dhawan 1.24 - - - -
hdfc mutual fund - hdfc n... 5.24 - - - -
invesco india midcap fund... 2.02 - - - -
mirae asset arbitrage fun... 2.90 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
Credit INDIA RATINGS & RESEARCH
Credit INDIA RATINGS & RESEARCH
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research Geojit
Research Report By:
Research HDFC Securities
Research ICICI Securities Limited
Research Motilal Oswal
Research Reliance Securities
Research Prabhudas Lilladhar
Research HDFC Securities
Research Geojit BNP Paribas

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q3FY25
Concall Q3FY25
Concall Q2FY26
Concall Q1FY26
Concall Q1FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY26
Presentation Q4FY26
Presentation Q4FY25
Presentation Q4FY24
Presentation Q3FY24
Presentation Q3FY19
Presentation Q2FY24
Presentation Q1FY26
Presentation Q1FY24

Company News

Glenmark Pharmaceuticals informs about allotment of shares under ESOP 10 Aug, 5:27 PM Glenmark Pharmaceuticals rises as its arm launches Sugammadex Injection 29 Jul, 9:26 AM Glenmark Pharmaceuticals’ arm launches Sugammadex Injection 29 Jul, 9:05 AM Glenmark Pharmaceuticals informs about press release 21 Jul, 10:22 AM Glenmark Pharma’s arm gets USFDA’s nod to expand use of RYALTRIS Nasal Spray 21 Jul, 9:30 AM Glenmark Pharmaceuticals informs about press release 6 Jul, 9:59 AM Glenmark Pharmaceuticals’ arm launches Olanzapine for Injection 6 Jul, 9:30 AM Glenmark Pharmaceuticals informs about media release 2 Jul, 11:44 AM USFDA completes GMP inspection at Glenmark Pharmaceuticals’ Goa facility 1 Jul, 11:19 AM Glenmark Pharmaceuticals’ arm launches Methylene Blue Injection 17 Jun, 9:50 AM Glenmark Pharmaceuticals informs about press release 17 Jun, 9:22 AM Glenmark Pharmaceuticals informs about press release 11 Jun, 3:26 PM Glenmark Pharmaceuticals gains as its arm launches Winlevi across key markets in Europe 11 Jun, 11:50 AM Glenmark Pharmaceuticals’ arm launches Winlevi across key markets in Europe 11 Jun, 11:20 AM Glenmark Pharmaceuticals informs about investor presentation 9 Jun, 4:57 PM Glenmark Pharmaceuticals inches up as its arm launches Lacosamide Injection 5 Jun, 9:55 AM Glenmark Pharmaceuticals informs about media release 5 Jun, 9:37 AM Glenmark Pharmaceuticals informs about transcript of earnings call 5 Jun, 9:36 AM Glenmark Pharmaceuticals’ arm launches Lacosamide Injection 5 Jun, 9:28 AM Glenmark Pharmaceuticals reports multi-fold jump Q4 consolidated net profit 30 May, 3:39 PM Glenmark Pharmaceuticals moves up as its arm launches Vancomycin Hydrochloride for Injection 18 May, 12:50 PM Glenmark Pharmaceuticals’ arm launches Vancomycin Hydrochloride for Injection 18 May, 10:39 AM Glenmark Pharmaceuticals informs about media release 18 May, 9:35 AM Glenmark Pharmaceuticals gets USFDA’s final nod for Progesterone Vaginal Inserts 9 Apr, 11:38 AM Glenmark Pharmaceuticals submits press release 9 Apr, 10:14 AM Glenmark Pharmaceuticals launches GLIPIQ in India 23 Mar, 10:21 AM Glenmark Pharmaceuticals informs about media release 21 Mar, 9:53 AM Glenmark Pharmaceuticals gets final nod for Fluticasone Propionate Nasal Spray 19 Mar, 11:52 AM Glenmark Pharmaceuticals’ arm launches Milnacipran Hydrochloride tablets 19 Mar, 10:22 AM Glenmark Pharmaceuticals informs about media release 19 Mar, 9:47 AM Glenmark Pharmaceuticals informs about media release 19 Mar, 9:46 AM Glenmark Pharma’s arm to launch Potassium Phosphates Injection 16 Mar, 12:12 PM Glenmark Pharmaceuticals informs about media release 16 Mar, 9:46 AM Glenmark Pharmaceuticals’ arm gets USFDA’s nod for Fluticasone Propionate Inhalation Aerosol 4 Mar, 11:42 AM Glenmark Pharmaceuticals informs about press release 4 Mar, 9:33 AM Glenmark Pharmaceuticals rises as its arm to launch Sodium Phosphates Injection 27 Feb, 12:05 PM Glenmark Pharmaceuticals’ arm to launch Sodium Phosphates Injection 27 Feb, 11:40 AM Glenmark Pharmaceuticals informs about updates 27 Feb, 10:11 AM Glenmark Pharmaceuticals informs about board meeting 19 Jan, 5:37 PM Glenmark Pharmaceuticals informs about ESG rating 5 Jan, 4:59 PM Glenmark Pharma gains as its arm launches Epinephrine Injection 23 Dec, 11:20 AM Glenmark Pharma’s arm launches Epinephrine Injection 23 Dec, 11:00 AM Glenmark Pharmaceuticals informs about media release 23 Dec, 9:37 AM Glenmark Pharmaceuticals’ arm enters into agreement for Aumolertinib 17 Dec, 10:13 AM Glenmark Pharma gains as its arm to launch Leucovorin Calcium for Injection USP 11 Dec, 10:50 AM Glenmark Pharma’s arm to launch Leucovorin Calcium for Injection USP 11 Dec, 9:48 AM USFDA completes Pre-Approval Inspection at Glenmark Pharmaceuticals’ Aurangabad facility 1 Dec, 11:18 AM Glenmark Pharmaceuticals informs about press release 1 Dec, 9:47 AM Glenmark Pharmaceuticals soars on getting EIR with VAI status for USA manufacturing facility 27 Nov, 2:54 PM Glenmark Pharmaceuticals informs about update 27 Nov, 11:10 AM

Glenmark Pharma. Stock Price Analysis and Quick Research Report. Is Glenmark Pharma. an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Glenmark Pharma.. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Glenmark Pharma. has a PE ratio of 309.862068965517 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Glenmark Pharma. has ROA of -0.5995% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Glenmark Pharma. has a Current ratio of 1.6612.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Glenmark Pharma. has a ROE of -0.8255%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Glenmark Pharma. has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Glenmark Pharma. has reported revenue growth of -8.5224% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Glenmark Pharma. for the current financial year is 12.7652294125934%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Glenmark Pharma. is Rs 2.5 and the yield is 0.1115%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Glenmark Pharma. is Rs 7.25. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Glenmark Pharma. in Ticker for free. Also, one can get the intrinsic value of Glenmark Pharma. by using Valuation Calculators, which are available with a Finology ONE subscription. 

Glenmark Pharma. FAQs

Q1. What is Glenmark Pharma. share price today?
Ans: The current share price of Glenmark Pharma. is Rs 2246.5.

Q2. What is the market capitalisation of Glenmark Pharma.?
Ans: Glenmark Pharma. has a market capitalisation of Rs 63401.7725648 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Glenmark Pharma.?
Ans: The PE ratio of Glenmark Pharma. is 309.862068965517 and the P/B ratio of Glenmark Pharma. is 2.54807051571064, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Glenmark Pharma. share?
Ans: The 52-week high share price of Glenmark Pharma. is Rs 2474, and the 52-week low share price of Glenmark Pharma. is Rs 1792.6.

Q5. Does Glenmark Pharma. pay dividends?
Ans: Currently, Glenmark Pharma. pays dividends. Dividend yield of Glenmark Pharma. is around 0.1115%.

Q6. What are the face value and book value of Glenmark Pharma. shares?
Ans: The face value of Glenmark Pharma. shares is Rs 1, while the book value per share of Glenmark Pharma. is around Rs 881.6475. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Glenmark Pharma.?
Ans: Glenmark Pharma. has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Glenmark Pharma.?
Ans: The ROE of Glenmark Pharma. is -0.8255% and ROCE of Glenmark Pharma. is -0.7591%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Glenmark Pharma. a good buy for the long term?
Ans: The Glenmark Pharma. long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Glenmark Pharma. undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Glenmark Pharma. appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Glenmark Pharma.’s financials?
Ans: You can review Glenmark Pharma.’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Glenmark Pharma.

Glenmark Pharmaceuticals Ltd Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis 

 

Welcome to the Glenmark Pharmaceuticals Ltd stock analysis page tailored for college student stock investors seeking comprehensive insights. In this section, we will delve into various aspects of Glenmark Pharmaceuticals Ltd, including its share price, balance sheet, annual report, dividend, quarterly results, stock price, price chart, news, concall transcripts, investor presentations, promoters, and shareholders. Our objective is to equip you with valuable information to make informed investment decisions.

Glenmark Pharmaceuticals Ltd Share Price Analysis 

Evaluate the share price of Glenmark Pharmaceuticals Ltd to gauge its market performance. Utilize Ticker pre-built screening tools to assess the current stock price and compare it with industry peers. Leverage our platform's market trends and indicators to aid your analysis as a college student stock investor seeking to assess the potential of this stock.

Glenmark Pharmaceuticals Ltd Balance Sheet Evaluation 

Evaluate the balance sheet of Glenmark Pharmaceuticals Ltd to understand the company's financial stability and performance. Leverage our premium features, including DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis, to calculate the fair value based on the balance sheet. These tools provide a comprehensive view of the company's financials, empowering you to make informed investment decisions.

Glenmark Pharmaceuticals Ltd Annual Report Review 

Access the annual reports of Glenmark Pharmaceuticals Ltd for valuable insights into the company's performance, strategies, and future prospects. Downloadable versions of the annual reports are available on Ticker, facilitating thorough analysis. College student stock investors will find these reports invaluable for understanding the company's long-term vision and growth trajectory.

Glenmark Pharmaceuticals Ltd Dividend Analysis 

Evaluate the dividend policy and history of Glenmark Pharmaceuticals Ltd. Ticker pre-built screening tools assist in analyzing the company's dividend payment history and potential. Monitor the dividend yield to assess the income potential associated with this stock. Dividend analysis is essential for college student stock investors, as it provides insights into how the company rewards its shareholders.

Glenmark Pharmaceuticals Ltd Quarterly Results Examination 

Analyze the quarterly financial results of Glenmark Pharmaceuticals Ltd to evaluate its performance and growth trends. Our premium features, such as DCF Analysis, Earnings Multiple Approach, and DuPont Analysis, facilitate fair value calculations based on the quarterly results. This analysis delves into the company's revenue, expenses, and profitability.

Glenmark Pharmaceuticals Ltd Stock Price Monitoring 

Stay updated on the stock price of Glenmark Pharmaceuticals Ltd and track market trends. Our platform provides a detailed stock price chart, enabling historical data analysis and identification of patterns and trends. Understanding the stock's performance over time is crucial for college student stock investors seeking to make well-informed investment decisions.

Glenmark Pharmaceuticals Ltd Price Chart Analysis 

Analyze the price chart of Glenmark Pharmaceuticals Ltd to identify patterns and trends that can influence investment decisions. Ticker user-friendly interface allows for visual exploration of the stock's historical performance, enhancing understanding of market dynamics. Utilize this information to identify potential entry and exit points.

Glenmark Pharmaceuticals Ltd News Updates 

Stay updated with the latest news articles about Glenmark Pharmaceuticals Ltd. Ticker dedicated news section on the website offers valuable information on the company's recent developments, market trends, and industry updates. Staying informed is pivotal for college student stock investors looking to make sound investment decisions amid the dynamic market landscape.

Glenmark Pharmaceuticals Ltd Conference Call Transcripts 

Access conference call transcripts of Glenmark Pharmaceuticals Ltd to gain insights into the company's operations, strategies, and future plans. These transcripts comprehensively outline key discussions and announcements made during the company's conference calls. Utilize this information to gain a deeper understanding of the company's direction and prospects.

Glenmark Pharmaceuticals Ltd Investor Presentations 

Explore investor presentations of Glenmark Pharmaceuticals Ltd to obtain valuable insights into the company's growth potential and investment opportunities. These presentations provide an overview of the company's value proposition, strategies, and financial performance. Analyzing investor presentations can offer college student stock investors a better understanding of the company's vision and plans.

Glenmark Pharmaceuticals Ltd Promoters & Shareholders 

Understand the ownership structure of Glenmark Pharmaceuticals Ltd by reviewing its key promoters and major shareholders. Gain insights into ownership concentration and potential alignment of interests. Ticker provides detailed information about the company's promoters and major shareholders, enabling informed investment decisions and understanding of the key stakeholders driving the company's growth.

Glenmark Pharmaceuticals Ltd ROCE

Glenmark Pharmaceuticals Ltd's Return on Capital Employed (ROCE) is a vital financial metric that evaluates the company's profitability and efficiency in utilizing its capital investments. Our stock analysis page provides comprehensive ROCE data for Glenmark Pharmaceuticals Ltd, allowing investors to assess the company's ability to generate returns from the capital employed. By analyzing this ratio, investors can gain insights into the company’s financial performance. Access the detailed ROCE information for Glenmark Pharmaceuticals Ltd in the financials table or ratio section on this page.

Glenmark Pharmaceuticals Ltd EBITDA

Glenmark Pharmaceuticals Ltd's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is a key measure for evaluating the company's operational performance and profitability. Our stock analysis page offers comprehensive EBITDA data for Glenmark Pharmaceuticals Ltd, enabling investors to assess the company's core earnings and financial health. Access the detailed EBITDA figures for Glenmark Pharmaceuticals Ltd in the financials table or ratio section on this page.

Glenmark Pharmaceuticals Ltd DPS

Glenmark Pharmaceuticals Ltd's Dividends Per Share (DPS) indicate the portion of profits distributed to shareholders as dividends. Monitoring DPS is essential for investors seeking a consistent income from dividends. Our stock analysis page features the DPS data for Glenmark Pharmaceuticals Ltd, enabling investors to track the company's dividend history and payout ratio. Access the detailed DPS information for Glenmark Pharmaceuticals Ltd in the financials table or ratio section on this page.

Glenmark Pharmaceuticals Ltd EPS

Earnings Per Share (EPS) is a fundamental financial metric that measures Glenmark Pharmaceuticals Ltd's profitability on a per-share basis. Our stock analysis page provides detailed EPS information for Glenmark Pharmaceuticals Ltd, allowing investors to assess the company's earnings performance and growth potential. Access the comprehensive EPS figures for Glenmark Pharmaceuticals Ltd in the financials table or ratio section on this page to make informed investment decisions. 

Glenmark Pharmaceuticals Share Capital Stability

Glenmark Pharmaceuticals has shown a constant Share Capital figure at Rs 28.22 Cr from March 2020 to March 2024, indicating a stable equity structure without any dilution to the shareholders' value during this period.

Glenmark Pharmaceuticals Reserves Growth

The Total Reserves of Glenmark Pharmaceuticals have seen a significant rise from Rs 13,198.05 Cr in March 2020 to Rs 22,942.40 Cr by March 2024. This robust increase in reserves underscores the company's solid financial health and its capability to support future growth.

Reducing Debt in Glenmark Pharmaceuticals' Financials

A notable aspect of Glenmark Pharmaceuticals' balance sheet is the reduction of Borrowings to zero by March 2024, down from Rs 3,131.17 Cr in March 2020. This debt clearance is a positive sign, reflecting the company's strong focus on achieving a debt-free status, enhancing its financial resilience.

Investments and Asset Growth at Glenmark Pharmaceuticals

Glenmark Pharmaceuticals' Investments have nearly tripled, moving from Rs 4,713.93 Cr in March 2020 to Rs 12,964.79 Cr by March 2024. Additionally, the consistent growth in Assets, from Rs 19,738.33 Cr in March 2020 to Rs 31,409.72 Cr in March 2024, highlights the company's aggressive expansion and reinvestment in its future.

This data is an analysis for the Standalone Balance sheet of Glenmark Pharmaceuticals. Investors looking into the pharmaceutical sector can also explore broader market trends on NSE/BSE indices, upcoming IPOs, or sectoral analyses for a comprehensive investment strategy.

Read More
X